Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden
· Delayed Price · Currency is SEK 3.650
-0.185 (-4.82%)
May 13, 2025, 5:29 PM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 46.7 | 46.1 | 57.6 | 22.6 | 38.2 | 40.66 | Upgrade
|
| Revenue | 46.7 | 46.1 | 57.6 | 22.6 | 38.2 | 40.66 | Upgrade
|
| Revenue Growth (YoY) | -25.75% | -19.96% | 154.87% | -40.84% | -6.05% | -50.75% | Upgrade
|
| Cost of Revenue | 18.6 | 11.6 | 11 | 142.6 | 96.6 | 185.17 | Upgrade
|
| Gross Profit | 28.1 | 34.5 | 46.6 | -120 | -58.4 | -144.51 | Upgrade
|
| Selling, General & Admin | 215.6 | 215.3 | 172.8 | 74.3 | 44.6 | 32.15 | Upgrade
|
| Research & Development | 143.9 | 146.2 | 194 | - | - | - | Upgrade
|
| Other Operating Expenses | -13.3 | -5.2 | -8.9 | - | -0.3 | - | Upgrade
|
| Operating Expenses | 346.2 | 356.3 | 357.9 | 77 | 46.8 | 32.55 | Upgrade
|
| Operating Income | -318.1 | -321.8 | -311.3 | -197 | -105.2 | -177.06 | Upgrade
|
| Interest Expense | -23.7 | -17.6 | -4.2 | -0.1 | -0.2 | -0 | Upgrade
|
| Interest & Investment Income | 7.6 | 6.9 | 4.9 | 0.9 | 0.1 | 0.16 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.3 | -6.3 | -13.4 | 2.4 | 0.6 | -1.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.3 | -4.5 | -2.8 | - | 0.2 | 0 | Upgrade
|
| Pretax Income | -331.2 | -343.3 | -326.8 | -193.8 | -104.5 | -178.02 | Upgrade
|
| Income Tax Expense | 0.3 | 0.3 | 0.1 | - | - | - | Upgrade
|
| Net Income | -331.5 | -343.6 | -326.9 | -193.8 | -104.5 | -178.02 | Upgrade
|
| Net Income to Common | -331.5 | -343.6 | -326.9 | -193.8 | -104.5 | -178.02 | Upgrade
|
| Shares Outstanding (Basic) | 323 | 307 | 257 | 194 | 180 | 67 | Upgrade
|
| Shares Outstanding (Diluted) | 323 | 311 | 260 | 194 | 180 | 67 | Upgrade
|
| Shares Change (YoY) | 19.69% | 19.57% | 33.86% | 7.97% | 166.96% | 30.54% | Upgrade
|
| EPS (Basic) | -1.03 | -1.12 | -1.27 | -1.00 | -0.58 | -2.64 | Upgrade
|
| EPS (Diluted) | -1.03 | -1.12 | -1.30 | -1.00 | -0.60 | -2.64 | Upgrade
|
| Free Cash Flow | -239 | -227.9 | -278.4 | -173.5 | -130.3 | -134.66 | Upgrade
|
| Free Cash Flow Per Share | -0.74 | -0.73 | -1.07 | -0.89 | -0.72 | -2.00 | Upgrade
|
| Gross Margin | 60.17% | 74.84% | 80.90% | - | -152.88% | - | Upgrade
|
| Operating Margin | -681.16% | -698.05% | -540.45% | -871.68% | -275.39% | -435.43% | Upgrade
|
| Profit Margin | -709.85% | -745.34% | -567.53% | -857.52% | -273.56% | -437.81% | Upgrade
|
| Free Cash Flow Margin | -511.78% | -494.36% | -483.33% | -767.70% | -341.10% | -331.18% | Upgrade
|
| EBITDA | -315 | -319.1 | -310.2 | -195.8 | -104 | -176.88 | Upgrade
|
| EBITDA Margin | - | - | - | - | -272.25% | - | Upgrade
|
| D&A For EBITDA | 3.1 | 2.7 | 1.1 | 1.2 | 1.2 | 0.18 | Upgrade
|
| EBIT | -318.1 | -321.8 | -311.3 | -197 | -105.2 | -177.06 | Upgrade
|
| EBIT Margin | - | - | - | - | -275.39% | - | Upgrade
|
| Revenue as Reported | - | - | - | 22.6 | 38.5 | 40.66 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.